drugset / Trial / NCT01604408

A Study in Older Participants Who Have Fallen and Have Muscle Weakness

NCT01604408

Phase 2 Completed 201 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

LY2495655 is an investigational drug being tested for muscle wasting.

Timeline

Start
2012-05
Primary completion
2013-09
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject LANDOGROZUMAB Monoclonal antibody 315 mg Subcutaneous

Indications